A pregnant woman is considered at risk of preterm birth before 34 weeks' gestation. The team is discussing whether prenatal magnesium sulphate for fetal neuroprotection is supported by current randomized trial evidence.
What does the evidence in this abstract support regarding magnesium sulphate compared with placebo in this setting?